Payment overview · 2025
General Payments
$157.09
7 reported records · 6 companies
Healthcare provider profile · identity verified
Joseph Tran
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · WICHITA, KS · NPI 1649916354
Verified facts
What the public records show
CMS Open Payments records show Joseph Tran received $157.09 in general payments during 2025 across 7 reported records.
Cochlear Americas accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cochlear Americas | Unresolved — no canonical attribution shown | $55.86 | 35.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.02 | 19.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.52 | 14.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.24 | 11.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.59 | 10.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.86 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $157.09 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BAHA Normalized: baha |
Device | Cochlear Americas | $55.86 | 1 | 2025 |
Source payment records
|
|||||
| COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Normalized: cochlear nucleus ci632 cochlear implant with slim modiolar electrode |
Device | Cochlear Americas | $55.86 | 1 | 2025 |
Source payment records
|
|||||
| OSIA OSI300 IMPLANT Normalized: osia osi300 implant |
Device | Cochlear Americas | $55.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 97 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 21 |
| Simvastatin | Simvastatin | 76 | 18 |
| Gabapentin | Gabapentin | 70 | 26 |
| Potassium Chloride | Potassium Chloride | 66 | 20 |
| Omeprazole | Omeprazole | 64 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 56 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 15 |
| Meloxicam | Meloxicam | 54 | 15 |
| Losartan Potassium | Losartan Potassium | 50 | 16 |
| Eliquis | Apixaban | 48 | suppressed |
| Lisinopril | Lisinopril | 48 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 40 |
| Lidocaine | Lidocaine | 45 | 23 |
| Metformin Hcl | Metformin Hcl | 44 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | suppressed |
| Furosemide | Furosemide | 36 | 21 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Prednisone | Prednisone | 31 | 28 |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 17 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 21 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Mupirocin | Mupirocin | 18 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 16 |
| Fluconazole | Fluconazole | 16 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $157.09 · 7 records | Cochlear Americas | BAHA, COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE, DALVANCE, ELIQUIS, EVENITY, FARXIGA, LEQVIO, OSIA OSI300 IMPLANT, TEFLARO, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error